Recent Finacing
Recent Raise
Biscayne Neurotherapeutics is a clinical-stage biotech developing BIS-001, an extended-release synthetic huperzine A, for refractory focal epilepsies and pediatric Dravet syndrome, with technology licensed from Harvard, Yale, and USF.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors